First patient in IdeS phase II study transplanted
Hansa Medical AB (publ) today announced that the first patient after treatment with IdeS in a recently initiated Phase II study has been transplanted from a deceased donor.The phase II study that can include up to 10 patients is performed at Uppsala University Hospital and Karolinska University Hospital. The study will evaluate the safety, tolerability and efficacy of IdeS in kidney transplantation of sensitized patients. The patient was treated and transplanted in Uppsala. The study is also aimed at identifying the appropriate dose that in the majority of patients will result in anti-